Areas of Interest – North America
Please select a disease area to review all detailed information.
Friedreich Ataxia (FA)
- Ongoing developments in clinical research and real‑world evidence in FA.
- Educate healthcare professionals (HCPs) on early symptom recognition, diagnosis of FA, differential diagnoses, and the role of genetic counseling and testing.
- Increase HCP awareness of current guidelines for managing patients with FA.
- Supporting the education of healthcare professionals on applying mFARS (Friedreich Ataxia Rating Scale) for the Assessment and rating of Ataxia, and Activities of Daily Living (ADL) measures to track and assess disease progression.
- Expand knowledge on managing patients with FA, including how coordinated, continuous care plans support adherence and showcase effective team‑based care models.
- Increase HCP understanding of how age of onset influences disease progression, including tools used across clinical disciplines to assess severity and the importance of proactive management for all patients.
Lupus
- Natural history of cutaneous lupus erythematosus (CLE), including disease course and progression.
- How disease activity is measured in cutaneous lupus.
- Impact of scarring and long‑term damage on health outcomes and quality of life.
- Factors contributing to delayed diagnosis of systemic or cutaneous lupus, including challenges in patients with skin of color.
- Monitoring and managing systemic lupus using guidelines, therapeutic response measures, and patient‑focused outcomes.
- Burden of skin and joint symptoms in systemic lupus and their effects on quality of life.
- How social determinants of health influence outcomes in systemic and cutaneous lupus.
Multiple Sclerosis
- Key considerations and clinical management approaches for transitioning patients from high‑efficacy therapies (e.g., B‑cell–depleting treatments) to other fumarate therapies